“…One major limit has been the lack of appropriate delivery systems required to prevent degradation of pDNA/mRNA, and to enable cell type-specific delivery [ 125 , 126 ]. Insofar, it is not surprising that by now virus-based gene therapies including oncolytic viruses [ 471 , 474 , 475 , 477 , 478 ], and cell-based immunotherapeutics, namely CAR-T cell therapies [ 28 , 277 , 562 , 563 , 564 ], demonstrated more successful for tumor therapy, and have been approved for clinical treatment. However, in the last years, the development of biocompatible, cell targeting NPs, especially of liposomal carriers [ 565 ], has strongly improved the efficacy of e.g., mRNA-based anti-tumor vaccines [ 71 , 72 ].…”